FK506 + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconjunctivitis
Conditions
Keratoconjunctivitis, Conjunctivitis
Trial Timeline
Feb 1, 2004 → Sep 1, 2004
NCT ID
NCT00567762About FK506 + placebo
FK506 + placebo is a phase 3 stage product being developed by Astellas Pharma for Keratoconjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00567762. Target conditions include Keratoconjunctivitis, Conjunctivitis.
What happened to similar drugs?
1 of 8 similar drugs in Keratoconjunctivitis were approved
Approved (1) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00567762 | Phase 3 | Completed |
Competing Products
15 competing products in Keratoconjunctivitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK506 | Astellas Pharma | Phase 3 | 40 |
| OTX-101 0.09% | Sun Pharmaceutical | Phase 3 | 40 |
| OTX-101 0.05% + OTX-101 0.09% + Vehicle | Sun Pharmaceutical | Phase 2/3 | 38 |
| cyclosporine + vehicle of OTX-101 | Sun Pharmaceutical | Phase 3 | 40 |
| INS365 Ophthalmic Solution | Merck | Phase 3 | 40 |
| Pimecrolimus + Vehicle | Novartis | Phase 2 | 35 |
| Cyclosporine A + Dexamethasone | Novartis | Approved | 43 |
| Rebamipide | Novartis | Phase 3 | 40 |
| Rebamipide | Novartis | Phase 3 | 40 |
| Tasocitinib + Tasocitinib + vehicle for Tasocitinib | Pfizer | Phase 2 | 27 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 31 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo | Rigel Pharmaceuticals | Phase 1 | 23 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo | Rigel Pharmaceuticals | Phase 2 | 29 |
| CF101 | Can Fite Biopharma | Phase 3 | 30 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 25 |